Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liming Gao

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Cell|September 21, 2024
m<sup>6</sup>A-modified cenRNA stabilizes CENPA to ensure centromere integrity in cancer cellsZihong Kang, Ruimeng Li, Chang Liu, et al.
National Science Review|February 17, 2025
Ultra-broadband near-field Josephson microwave microscopyPing Zhang, Yang-Yang Lyu, Jingjing Lv, et al.
JAMA Oncology|July 21, 2022
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical TrialJiachen Xu, Zheng Liu, Hua Bai, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Cell|September 21, 2024
m<sup>6</sup>A-modified cenRNA stabilizes CENPA to ensure centromere integrity in cancer cellsZihong Kang, Ruimeng Li, Chang Liu, et al.
National Science Review|February 17, 2025
Ultra-broadband near-field Josephson microwave microscopyPing Zhang, Yang-Yang Lyu, Jingjing Lv, et al.
JAMA Oncology|July 21, 2022
Evaluation of Clinical Outcomes of Icotinib in Patients With Clinically Diagnosed Advanced Lung Cancer With EGFR-Sensitizing Variants Assessed by Circulating Tumor DNA Testing: A Phase 2 Nonrandomized Clinical TrialJiachen Xu, Zheng Liu, Hua Bai, et al.
Signal Transduction and Targeted Therapy|December 18, 2025
Novel CDK2/4/6 inhibitor culmerciclib (TQB3616) plus fulvestrant in previously treated, HR-positive, HER2-negative advanced breast cancer: a randomized, double-blind, phase 3 trialYongmei Yin, Qingyuan Zhang, Tao Sun, et al.
Pageof 9